August 05, 2026
A Texas federal judge has denied Revive Rx's bid to end Eli Lilly and Co.'s remaining unfair competition claims over the compounding pharmacy's sales of allegedly unapproved tirzepatide weight loss drugs that Eli Lilly says compete with Mounjaro and Zepbound, rejecting Revive's argument that compounded drugs fall outside state "new drug" laws.
September 19, 2023
A little more than a year after releasing a popular billion-dollar drug marketed at people with Type 2 diabetes, Eli Lilly & Co. filed a flurry of lawsuits on Tuesday against spas and other retailers that it says are selling counterfeit or compounded versions of the drug as a weight loss cure.